2
Registered trials
2
Recruiting
2
Unique sponsors
5
Unique IMPs
0
Commercial trials
Drug classes (ATC)
L
Oncology (ATC L)
1
—
ATC code not specified
1
Mechanism of action (INN-stem analysis)
Unknown / small molecule
3 substances
Checkpoint inhibitor (CTLA-4)
1 substance
Checkpoint inhibitor (PD-1)
1 substance
Phase II:
1
Phase I (Other):
1
Phase II
1 trial-
RecruitingGrupo Espanol De Investigacion En Neurooncologia AcademicTUVUSERTIB
Phase I (Other)
1 trial-
RecruitingUZ Brussel AcademicCD1C+/CD141+ MYELOID DENDRITIC CELLS ISOLATED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS; IPILIMUMAB; NIVOLUMAB; NIVOLUMAB, RELATLIMAB
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| UZ Brussel | Academic | 1 | Phase I (Other) | 1 |
| Grupo Espanol De Investigacion En Neurooncologia | Academic | 1 | Phase II | 1 |
New trials by year
2024
1
2025
1